In Brief: Alpharma
This article was originally published in The Tan Sheet
Executive Summary
Alpharma: Gert Wilhelm Munthe is new president and chief operating officer of the private label manufacturer. Munthe, formerly president and CEO of Oslo, Norway-based NetCom ASA, has been a member of the Alpharma board for four years. He reports to Alpharma Chairman and CEO Einar Sissener and is expected to succeed Sissener when he steps down from the CEO position in 1999; Sissener will continue as chairman of the board. The company's five Strategic Business Unit presidents, as well as the chief financial officer, now report to Munthe. Alpharma recently received tentative FDA approval for its ANDA for ibuprofen oral suspension, comparable to McNeil's Children's Motrin, for which marketing exclusivity expires June 16 ("The Tan Sheet" Jan. 19, In Brief)...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning